Liver Cancer Trial, Recruiting NCT07538882 Sponsor: Beijing Tsinghua Chang Gung Hospital Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT07538882
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older.
  • People who have been recently diagnosed with, or are suspected of having, primary liver cancer (a cancer that started in the liver), later confirmed by tissue testing or according to recognised Chinese liver cancer guidelines.
  • People who have a complete set of baseline health records collected during the enrolment period, including medical history, a physical performance score, blood tests (such as liver function, clotting, and tumour markers like AFP), and a contrast-enhanced CT scan of the abdomen.
  • People (or their legal representative) who have provided written consent for their clinical information to be used in this trial.

Who may not be able to join:

  • People whose liver cancer has spread from another part of the body (secondary or metastatic liver cancer), or who have another serious cancer elsewhere in the body at the same time.
  • People whose required baseline scans or blood tests are incomplete, making it impossible for the trial site to accurately calculate their cancer stage (for example, if information needed to calculate a Child-Pugh score is missing).
  • People who have already received any anti-cancer treatment for liver cancer before enrolment in this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jiahong Dong, Beijing Tsinghua Changgeng Hospital

Phone: +8618632957579

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Beijing Tsinghua Chang Gung Hospital
Registry
ClinicalTrials.gov
Start date
13 April 2026
Est. completion
13 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Improvement in Overall Accuracy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov